ArticlePlants (Basel, Switzerland)2023
Evaluations of Andrographolide-Rich Fractions of
Article in Plants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- High-Throughput Virtual Screening of Phytochemicals From Indian Medicinal Plants for the Identification of Potential Inhibitors Against NS2B-NS3 Protease of Dengue Virus.Biotechnology and applied biochemistry · 2026Article
- Portable, Rapid, and Cost-Effective Smartphone-Based Colorimetric Quantification of Total Lactones inPharmaceuticals (Basel, Switzerland) · 2026Article
- Clinical pharmacokinetics and pharmacometabolomics of Andrographis paniculata capsules: Bridging drug disposition and metabolic response to precision medicine.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Andrographolide Attenuates Sepsis-Induced Acute Lung InjuryEndocrine, metabolic & immune disorders drug targets · 2026Article
- A metabolomics approach to target the effect of histone protein methyltransferase-specific probe UNC1999 on cryptic metabolites in an endophytic fungusFrontiers in microbiology · 2026Article
- Enhanced auxin signalling, increased andrographolide biosynthesis, and antioxidant defence in gold nanoparticles-elicited3 Biotech · 2025Article
- Article
- Andrographolide as a Multi-Target Therapeutic Agent in Diabetic Nephropathy: Insights into STAT3/PI3K/Akt Pathway Modulation.Biomolecules & therapeutics · 2025Article
- Rhodomyrtone-rich fractions fromVeterinary world · 2025Article
- Phytochemical Composition, Bioactive Compounds, and Antioxidant Properties of Different Parts ofLife (Basel, Switzerland) · 2023Article
- Andrographolide Mitigates DOCA-Salt-Induced Cardiac Hypertrophy by Regulating Calcium-Handling Genes.Journal of pharmacy & bioallied sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.